<DOC>
	<DOC>NCT00150787</DOC>
	<brief_summary>A double-blind follow-up trial assessing the long term safety of Levetiracetam as per adverse events reporting, physical and neurological examination and vital signs</brief_summary>
	<brief_title>Monotherapy With Levetiracetam or Carbamazepine in Patients Suffering From Epilepsy.</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsy, Tonic-Clonic</mesh_term>
	<mesh_term>Epilepsy, Generalized</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Subjects with a confirmed diagnosis of epilepsy. Subjects having experienced in the past unprovoked partial seizures (IA, IB, IC with clear focal origin), or generalized tonicclonic seizures (without clear focal origin), that are classifiable according to the International Classification of Epileptic Seizures Subjects coming from the N01061 monotherapy trial and for whom doubleblind continuation of investigational product is beneficial. Need for an additional AED.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Monotherapy, epilepsy</keyword>
	<keyword>Levetiracetam</keyword>
	<keyword>Keppra</keyword>
</DOC>